Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients
Terminated
Merck Sharp & Dohme Corp.
Phase 2
2014-09-30
Assessment of the safety, tolerability and early signs of efficacy of three times a day
orally administered BAY63-2521 in adult delta F508 homozygous Cystic Fibrosis patients not on
treatment with Orkambi
Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients
Terminated
Bayer
Phase 2
2014-09-30
Assessment of the safety, tolerability and early signs of efficacy of three times a day
orally administered BAY63-2521 in adult delta F508 homozygous Cystic Fibrosis patients not on
treatment with Orkambi
Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation
Completed
Medidata Solutions
Phase 2
2015-11-01
This will be a double-blind, randomized, placebo-controlled, parallel group study. The
purpose of this study is to investigate the efficacy and safety of Cavosonstat (N91115) in
adult patients with CF who are homozygous for the F508del-CFTR mutation and being treated
with lumacaftor/ivacaftor (Orkambi™).
Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation
Completed
Nivalis Therapeutics, Inc.
Phase 2
2015-11-01
This will be a double-blind, randomized, placebo-controlled, parallel group study. The
purpose of this study is to investigate the efficacy and safety of Cavosonstat (N91115) in
adult patients with CF who are homozygous for the F508del-CFTR mutation and being treated
with lumacaftor/ivacaftor (Orkambi™).
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
